BMY241206C48000
- 11.90
- +0.71+6.34%
Bristol-Myers Squibb Newsroom
Bernstein Adjusts Price Target on Bristol-Myers Squibb to $62 From $56, Keeps Market Perform Rating
Truist Financial Maintains Bristol-Myers Squibb(BMY.US) With Buy Rating
Truist Financial Reaffirms Their Buy Rating on Bristol-Myers Squibb (BMY)
Wells Fargo Maintains Bristol-Myers Squibb(BMY.US) With Hold Rating, Raises Target Price to $60
Wells Fargo Adjusts Price Target on Bristol-Myers Squibb to $60 From $52, Maintains Equalweight
Analysts Offer Insights on Healthcare Companies: Bristol-Myers Squibb (BMY) and MiMedx Group (MDXG)
HSBC Adjusts Bristol-Myers Squibb Price Target to $58 From $50, Maintains Hold Rating
Bristol-Myers Squibb Initiated at Peer Perform by Wolfe Research
Bristol-Myers Squibb Analyst Ratings
Wolfe Research Maintains Bristol-Myers Squibb(BMY.US) With Hold Rating
Daiwa Upgrades Bristol-Myers Squibb(BMY.US) to Buy Rating, Raises Target Price to $65
A Quick Look at Today's Ratings for Bristol-Myers Squibb(BMY.US), With a Forecast Between $60 to $73
Bristol-Myers Squibb Analyst Ratings
Goldman Sachs Adjusts Bristol-Myers Squibb Price Target to $65 From $62, Maintains Buy Rating
Leerink Partners Upgrades Bristol-Myers Squibb(BMY.US) to Buy Rating, Raises Target Price to $73
Citi Maintains Bristol-Myers Squibb(BMY.US) With Hold Rating, Raises Target Price to $60
Deutsche Bank Adjusts Price Target on Bristol-Myers Squibb to $55 From $48
Analysts' Top Healthcare Picks: Bristol-Myers Squibb (BMY), Agios Pharma (AGIO)
Bristol-Myers Squibb: Hold Rating Maintained Amid Positive Clinical Trials and Long-term EPS Concerns
Leerink Partners Maintains Bristol-Myers Squibb(BMY.US) With Hold Rating, Raises Target Price to $55